Back to Search
Start Over
Methyltransferases in cancer drug resistance: Unlocking the potential of targeting SMYD3 to sensitize cancer cells.
- Source :
-
Biochimica et biophysica acta. Reviews on cancer [Biochim Biophys Acta Rev Cancer] 2024 Nov; Vol. 1879 (6), pp. 189203. Date of Electronic Publication: 2024 Oct 24. - Publication Year :
- 2024
-
Abstract
- Drug resistance is a significant challenge in oncology and is driven by various mechanisms, among which a crucial role is played by enhanced DNA repair. Thus, targeting DNA damage response (DDR) factors with specific inhibitors is emerging as a promising therapeutic strategy. An important process involved in the modulation of DNA repair pathways, and hence in drug resistance, is post-translational modification (PTM). PTMs such as methylation affect protein function and are critical in cancer biology. Methylation is catalyzed by specific enzymes called protein methyltransferases. In recent years, the SET domain-containing N-lysine methyltransferase SMYD3 has emerged as a significant oncogenic driver. It is overexpressed in several tumor types and plays a signal-dependent role in promoting gastrointestinal cancer formation and development. Recent evidence indicates that SMYD3 is involved in the maintenance of cancer genome integrity and contributes to drug resistance in response to genotoxic stress by regulating DDR mechanisms. Several potential SMYD3 interactors implicated in DNA repair, especially in the homologous recombination and non-homologous end-joining pathways, have been identified by in silico analyses and confirmed by experimental validation, showing that SMYD3 promotes DDR protein interactions and enzymatic activity, thereby sustaining cancer cell survival. Targeting SMYD3, in combination with standard or targeted therapy, shows promise in overcoming drug resistance in colorectal, gastric, pancreatic, breast, endometrial, and lung cancer models, supporting the integration of SMYD3 inhibition into cancer treatment regimens. In this review, we describe the role played by SMYD3 in drug resistance and analyze its potential as a molecular target to sensitize cancer cells to treatment.<br />Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests<br /> (Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.)
- Subjects :
- Humans
DNA Repair drug effects
Antineoplastic Agents pharmacology
Antineoplastic Agents therapeutic use
Animals
DNA Damage drug effects
Protein Processing, Post-Translational
Drug Resistance, Neoplasm
Histone-Lysine N-Methyltransferase metabolism
Histone-Lysine N-Methyltransferase genetics
Histone-Lysine N-Methyltransferase antagonists & inhibitors
Neoplasms drug therapy
Neoplasms genetics
Neoplasms pathology
Subjects
Details
- Language :
- English
- ISSN :
- 1879-2561
- Volume :
- 1879
- Issue :
- 6
- Database :
- MEDLINE
- Journal :
- Biochimica et biophysica acta. Reviews on cancer
- Publication Type :
- Academic Journal
- Accession number :
- 39461625
- Full Text :
- https://doi.org/10.1016/j.bbcan.2024.189203